What is a FDA Inspection Readiness Assessment Checklist?

A FDA Inspection Readiness Assessment Checklist is a standardized inspection form used by quality director / regulatory affairs manager to ensure consistent pharmaceutical operations. It contains 27 inspection points organized into 6 sections. FREE PDF - FDA 21 CFR Parts 210/211 pharmaceutical cGMP inspection readiness assessment checklist for quality assurance directors and site compliance managers. Covers 21 CFR 211.22 quality control unit responsibilities, 21 CFR 211.100/211.192 batch record and investigation requirements, 21 CFR 211.160-166 laboratory controls, 21 CFR 211.42-58 facility and equipment qualification, and 21 CFR 211.68 personnel training. FDA warning letters result in import alerts and consent decrees when systemic cGMP failures are identified; FDA CPGM 7356.002 governs drug manufacturing inspections.

How often should I use this pharmaceutical checklist?

This checklist is designed to be completed semi-annual. Regular use ensures compliance with FDA 21 CFR Parts 210/211 cGMP Requirements and FDA Compliance Program Guidance Manual (CPGM) 7356.002 - Drug Manufacturing Inspections and helps identify issues before they become problems.

Can I download this FDA Inspection Readiness Assessment Checklist as a PDF?

Yes, you can download this checklist as a FREE PDF for printing or offline use. The checklist includes 27 fields across 6 sections and typically takes 60-90 minutes to complete.

How do I complete this pharmaceutical inspection checklist?

Start by filling in the header fields (date, inspector name, location). Then work through each of the 6 sections, marking Yes/No for each inspection point. Add notes for any issues found. Finally, complete the footer section with your signature. The entire process takes approximately 60-90 minutes.

What happens if I find issues during the pharmaceutical inspection?

Document any issues in the notes field, take photos as evidence, and assign corrective actions. POPProbe's mobile app allows you to instantly assign tasks to team members and track resolution. Critical issues should be escalated immediately per your organization's procedures.

Is this FDA Inspection Readiness Assessment Checklist template free?

Yes, this FDA Inspection Readiness Assessment Checklist template is completely free to download as a PDF. You can print it for immediate use. For digital completion with automatic reporting, photo capture, and offline capability, try POPProbe's free mobile app.

Can I use this checklist on my phone or tablet?

Yes, with POPProbe's mobile app you can complete this checklist on any smartphone or tablet. The app works offline, captures GPS location, allows photo attachments, and automatically syncs when connected. Perfect for field inspections and frontline teams.

How do I customize this pharmaceutical checklist for my organization?

With POPProbe, you can easily customize this FDA Inspection Readiness Assessment Checklist to match your organization's specific requirements. Add or remove inspection points, modify section names, adjust scoring criteria, and include your company branding. You can also set up automated scheduling to ensure the checklist is completed semi-annual and assign it to specific team members or locations.

What are common mistakes to avoid when completing pharmaceutical inspections?

Common mistakes include: rushing through items without proper verification, failing to document issues with photos or detailed notes, skipping sections that seem repetitive, not following up on previously identified problems, and completing inspections inconsistently. To avoid these, use a digital tool like POPProbe that enforces completion of all 27 fields, requires photo evidence, and tracks corrective actions automatically.

FDA Inspection Readiness Assessment Checklist

FDA cGMP inspections of pharmaceutical manufacturing facilities are conducted under 21 CFR Parts 210 and 211 using the FDA Compliance Program Guidance Manual 7356.002 (Drug Manufacturing Inspections). Readiness means the site can demonstrate, on demand during a multi-day inspection, that the quality system is functioning, that every batch record reflects the actual manufacturing process, that laboratory data is attributable and original, and that investigation and CAPA systems are closed and eff

Industry: Pharmaceutical
Frequency: Semi-Annual
Estimated Time: 60-90 minutes
Role: Quality Director / Regulatory Affairs Manager
Total Items: 19
Compliance: FDA 21 CFR Parts 210/211 cGMP Requirements, FDA Compliance Program Guidance Manual (CPGM) 7356.002 - Drug Manufacturing Inspections, FDA Pharmaceutical Quality System (PQS) Inspection Approach, EMA GMP Inspection Guidelines

Quality Control Unit Responsibilities and Authority (21 CFR 211.22)

Verify the Quality Control Unit (QCU) has written authority and documented procedures for all cGMP responsibilities, and that QCU approval and rejection authority is independent and not overridden. 21 CFR 211.22 is the foundational QCU authority provision; FDA investigators evaluate independence as their first systemic indicator.

Does the QCU have written procedures describing all of its responsibilities per 21 CFR 211.22(d), including batch record review, release and rejection authority, investigation oversight, annual product review oversight, and approval of all SOPs that affect product quality?
Is the QCU independent of production management in authority, reporting structure, and in practice (i.e., is there documented evidence that QCU has rejected batches or halted production without production management override in the past 12 months)?
Has the QCU reviewed and approved all master batch records, all SOPs currently in use, and all major changes within the past 12 months, with a document history log showing QCU approval dates and approver identity?
Has the Annual Product Review (APR) or Product Quality Review (PQR) been completed for all products manufactured in the past 12 months, and do the reviews evaluate batch failure trends, complaint trends, and OOS results?

Batch Record Completeness and Data Integrity (21 CFR 211.68 / 211.100 / 211.192)

Inspect a sample of executed batch records for completeness, contemporaneous recording, and compliance with the master batch record. 21 CFR 211.100 requires production to be conducted only according to written master records; 21 CFR 211.192 requires investigation of any unexplained discrepancy or failure. Data integrity is the most cited category in recent FDA warning letters.

Do all executed batch records contain entries made contemporaneously (at the time of performance), with original signatures and dates rather than backdated or reconstructed entries?
Are all batch record deviations, including those related to in-process checks, cleaning, and equipment use, formally documented in a deviation or nonconformance report and dispositioned by the QCU before batch release?
Is the most recent batch of each product that was released still within its expiry date, and is each released batch traceable via the batch number to a full set of completed batch records, Certificate of Analysis, and release signature?
Are all out-of-specification (OOS) results investigated through the full OOS investigation procedure (Phase I laboratory investigation, Phase II full investigation if Phase I is inconclusive), and are OOS investigations closed before the affected batch is released?

Laboratory Controls and Data Integrity (21 CFR 211.160-211.166)

Inspect laboratory records, instrument calibration logs, and raw data for compliance with 21 CFR 211.160-166. The FDA investigator in a drug manufacturing inspection will examine at least one analytical run from raw chromatographic data to final reported result to verify the data integrity chain.

Are all laboratory instruments listed in the equipment qualification status system, within their scheduled calibration interval, and tagged with a calibration sticker showing the calibration date and next due date?
Is all laboratory raw data (original chromatograms, spectra, titration records, calculation worksheets) retained in a secure system, attributable to the analyst who generated it, and protected from alteration after entry?
Are laboratory analyst training records current, including method-specific training for every test method the analyst runs, and is competency verified by a demonstrated performance test for new methods or after significant SOP revisions?

Facility, Equipment Qualification, and Cleaning Validation (21 CFR 211.42-211.67)

Inspect facility qualification status, equipment qualification records (IQ/OQ/PQ), and cleaning validation data. 21 CFR 211.42 requires that facilities be designed, constructed, and maintained to facilitate cleaning and to prevent contamination. Cleaning validation data must support the maximum allowable carryover calculation.

Are all critical manufacturing equipment items in a qualified (IQ/OQ/PQ completed) status, within the scheduled requalification interval, with any equipment changes since last qualification addressed through a change control assessment?
Is cleaning validation data available for all products manufactured on shared equipment, demonstrating that the cleaning procedure reduces residual active ingredient to at or below the maximum allowable carryover (MAC) limit, with the calculation basis documented?
Is the HVAC and environmental monitoring system qualified, with HEPA filter integrity tests, room pressure differentials, and differential readings recorded at the required frequency and within the facility's alert and action limits?

CAPA System and Investigation Effectiveness (21 CFR 211.192 / ICH Q10)

Inspect the CAPA system for completeness of root cause analysis, timeliness of action implementation, and evidence that CAPAs have been effective. The FDA investigator in CPGM 7356.002 evaluations specifically reviews the CAPA system for systemic failures -- a CAPA list with recurring categories indicates the root cause was not identified.

Are all open CAPAs within their scheduled completion dates, and are any overdue CAPAs justified by a formal extension with documented management approval and a revised target date?
For CAPAs that have been closed, is there an effectiveness check (verification that the problem has not recurred) conducted after a sufficient period following action implementation, with a positive effectiveness check documented in the CAPA record?

Personnel Training and Inspection Readiness (21 CFR 211.68 / CPGM 7356.002)

Verify personnel training records are current and accessible, and that site personnel understand how to interact with FDA investigators during an inspection. Investigator interactions during an unannounced inspection are a significant compliance risk; staff who are unprepared to respond accurately can inadvertently create documentary evidence of systemic problems.

Are all personnel with cGMP responsibilities (QCU, production, laboratory, warehouse) current on training for the SOPs governing their tasks, with training records demonstrating the specific SOP version and the date training was completed?
Is a documented inspection readiness procedure in place specifying: who greets the investigator, how to confirm investigator credentials, who accompanies the investigator at all times, how document requests are managed, and who answers technical questions?
Has the site conducted an internal cGMP inspection within the past 12 months using trained internal auditors, with the audit findings captured in a formal report, distributed to management, and each finding assigned to a CAPA?

Related Pharmaceutical Life Sciences Checklists

Why Use This FDA Inspection Readiness Assessment Checklist?

This fda inspection readiness assessment checklist helps pharmaceutical teams maintain compliance and operational excellence. Designed for quality director / regulatory affairs manager professionals, this checklist covers 19 critical inspection points across 6 sections. Recommended frequency: semi-annual.

Ensures compliance with FDA 21 CFR Parts 210/211 cGMP Requirements, FDA Compliance Program Guidance Manual (CPGM) 7356.002 - Drug Manufacturing Inspections, FDA Pharmaceutical Quality System (PQS) Inspection Approach, EMA GMP Inspection Guidelines. Regulatory-aligned for audit readiness and inspection documentation.

Frequently Asked Questions

What does the FDA Inspection Readiness Assessment Checklist cover?

This checklist covers 19 inspection items across 6 sections: Quality Control Unit Responsibilities and Authority (21 CFR 211.22), Batch Record Completeness and Data Integrity (21 CFR 211.68 / 211.100 / 211.192), Laboratory Controls and Data Integrity (21 CFR 211.160-211.166), Facility, Equipment Qualification, and Cleaning Validation (21 CFR 211.42-211.67), CAPA System and Investigation Effectiveness (21 CFR 211.192 / ICH Q10), Personnel Training and Inspection Readiness (21 CFR 211.68 / CPGM 7356.002). It is designed for pharmaceutical operations and compliance.

How often should this checklist be completed?

This checklist should be completed semi-annual. Each completion takes approximately 60-90 minutes.

Who should use this FDA Inspection Readiness Assessment Checklist?

This checklist is designed for Quality Director / Regulatory Affairs Manager professionals in the pharmaceutical industry. It can be used for self-assessments, team audits, and regulatory compliance documentation.

Can I download this checklist as a PDF?

Yes, this checklist is available as a free PDF download. You can also use it digitally in the POPProbe mobile app for real-time data capture, photo documentation, and automatic reporting.